Clinical Trials Browser

Phase 1 × Lymphoma × Crizotinib × Clear all

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 1 Terminated

44 enrolled 22 charts 1 FDA

Lymphoma, Neoplasms, Neuroblastoma